Acellular Tissue Engineered Vessel
Acellular Tissue Engineered Vessel es un fármaco en desarrollo de Humacyte. Tiene 6 ensayos clínicos registrados, 3 en marcha; lo más avanzado, fase 4.
HUMA Humacyte
Sus ensayos
| Para qué | Fase | Estado |
|---|---|---|
| To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis NCT05908084 | Fase 3 | En marcha, sin reclutar |
| An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury. NCT07762313 | Fase 3 | Aún sin reclutar |
| Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent Repair NCT07762794 | Fase 4 | Aún sin reclutar |
| Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma NCT03005418 | Fase 2/3 | Completado |
| Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis Access NCT07141641 | no aplica | No disponible temporalmente |
| Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System Injuries NCT03631056 | no aplica | Aprobado para comercializar |
¿Cuándo se esperan resultados? Está en el calendario, para quien tiene cuenta. Crear una cuenta.
Ensayos del registro público de ClinicalTrials.gov; noticias, de los documentos que la empresa presenta ante la SEC. No son recomendaciones de inversión.